依达拉奉对弥漫性轴索损伤患者NSE和MBP的影响及其神经保护作用

Effects of edaravone on NSE and MBP and its neuroprotective effect in patients with diffuse axonal injury

目的探讨依达拉奉对弥漫性轴索损伤(DAI)的神经元特异性烯醇化酶(NSE)和髓鞘碱性蛋白(MBP)的影响及神经保护作用。方法选择符合诊断标准的80例患者随机分为依达拉奉治疗组和对照组,每组40例,用酶联免疫法测定两组患者治疗前及治疗后第1、3、7、14d血清及脑脊液中NSE及MBP水平,治疗后7、14d对两组患者采用格拉斯哥评分(Gcs)标准进行评分,3个月后采用格拉斯哥预后评分(Gos)判断效果。结果依达拉奉治疗组DAI患者血清及脑脊液中NSE及MBP水平显著低于对照组,而且7、14d患者GCS评分较对照组有明显改善。3个月随访GOS发现,治疗组患者预后也明显好于对照组。结论依达拉奉可明显降低DAI患者血清及脑脊液中NSE及MBP表达水平,具有明确的神经保护作用。

Objective To explore the effects of edaravone on NSE and MBP and its neuroprotective effect in patients with diffuse ax- onal injury （DAI）. Methods 80 patients according to diagnostic criteria were selected and randomly divided into the edaravone treatment group and control group ,40 cases in each group. The content of NSE and MBP in serum and cerebrospinal fluid （CSF） were measured by en- zyme immunoassay before edaravone treatment and at 1,3,7,14 days after edaravone treatment. Glasgow point scale （GCS） were employed to value the nervous function sxore of two groups until 7 and 14 days, and three months later, Glasgow outcome scales （GOS） was used to value the effect of edaravone Results The content of NSE and MBP in serum and CSF of edaravone group was obviously lower than that of the con- trol group in 1,3,7,14 days GCS and GOS of edaravone group respectively at 7 or 14 days and 3 months later were significantly better than that of control group. Conclusion Edaravone can significantly reduce the NSE and MBP level in serum and CSF of DAI patients, showing obvi- ous neuroprotective effect.